BI/Lilly's Jardiance Takes On AstraZeneca's Farxiga With Heart Failure Approval

Blockbuster Gets EU Green Light For HFrEF

Cardiologists in Europe who have so far been unwilling to embrace the SGLT2 class now have two drugs approved for heart failure with reduced ejection fraction, with Jardiance soon to join Farxiga on the market, potentially attractive options especially for their diabetic patients.

heart failure money
• Source: Alamy

Boehringer Ingelheim GmbH and Eli Lilly and Company can finally start to claw back some market share from AstraZeneca PLC's Farxiga in the SGLT2 inhibitor heart failure space following a green light from the European Commission for expanded use of their diabetes blockbuster Jardiance.

Just a month after receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the Commission...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip